Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142602 | 1.00 | ALDH1A1 (0.55) | ALDH1A1ANPEPRNPEPDNPEPSLC7A5 | |
| SCHEMBL7100850 | 0.81 | SLC7A5 (0.61) | ALDH1A1ANPEPRNPEPDNPEPSLC7A5 | |
| SCHEMBL530834 | 0.81 | SLC7A5 (0.61) | ALDH1A1ANPEPRNPEPDNPEPSLC7A5 | |
| Levacetylleucine SCHEMBL18283362 | 0.77 | ALDH1A1 (0.79) | ALDH1A1SLC7A5LTA4HLAP3MEN1 | |
| Acetylleucine SCHEMBL20898469 | 0.77 | ALDH1A1 (0.79) | ALDH1A1SLC7A5LTA4HLAP3MEN1 | |
| SCHEMBL14771687 | 0.74 | ALDH1A1 (0.62) | ALDH1A1LTA4HLAP3MEN1LMNA | |
| SCHEMBL15810880 | 0.74 | ALDH1A1 (0.67) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL7669779 | 0.74 | ALDH1A1 (0.67) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL7669784 | 0.74 | ALDH1A1 (0.67) | ALDH1A1LAP3MEN1LMNAKMT2A | |
| SCHEMBL13822102 | 0.73 | ALDH1A1 (0.72) | ALDH1A1LAP3MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024018245-A1 | USE OF CALPAIN INHIBITORS FOR THE TREATMENT OF THE DIABETIC KIDNEY DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-01-25 | — | — | WO | claimed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | claimed |
| WO-2000021550-A2 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-04-20 | — | — | WO | claimed |
| WO-2024018245-A1 | USE OF CALPAIN INHIBITORS FOR THE TREATMENT OF THE DIABETIC KIDNEY DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-01-25 | — | — | WO | disclosed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| EP-3943090-A1 | EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF | Massachusetts Eye & Ear Infirmary (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3407901-B1 | EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20190010449-A1 | Expansion and Differentiation of Inner Ear Supporting Cells and Methods of Use Thereof | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-01-10 | — | — | US | disclosed |
| US-20150352196-A1 | Methods and Pharmaceutical Compositions for Prevention of Aging-Related Lesions | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2015-12-10 | — | — | US | disclosed |
| EP-2934573-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF AGING-RELATED LESIONS | Assistance Publique-Hôpitaux de Paris (FR) | 2015-10-28 | — | — | EP | disclosed |
| US-20020128189-A1 | Ubiquitination of the transcription factor E2A | PRESIDENT AND FELLOWS OF HARVARD COLLEGE, A MASSACHUSETTS CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020048746-A1 | Model for alzheimer's disease and other neurodegenerative diseases | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2002-04-25 | — | — | US | disclosed |
| WO-2002010768-A2 | MODEL FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-02-07 | — | — | WO | disclosed |
| US-6117887-A | ANTIPROLIFERATIVE AGENTS | CV THERAPEUTICS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| WO-2000021550-A2 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-04-20 | — | — | WO | disclosed |
| EP-0956031-A1 | INHIBITION OF 26S AND 20S PROTEASOME BY INDANONES | CV THERAPEUTICS, INC. (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5834487-A | ADMINISTERING DIPEPTIDE-SUBSTITUTED METHOXYINDANONES AS ENZYME INHIBITORS FOR TREATMENT OF CELL PROLIFERATION DISORDERS | CV THERAPEUTICS (US) | 1998-11-10 | — | — | US | disclosed |
| WO-1998013061-A1 | INHIBITION OF 26S AND 20S PROTEASOME BY INDANONES | CV THERAPEUTICS, INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997035961-A1 | UBIQUITINATION OF THE TRANSCRIPTION FACTOR E2A | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | ALDH1A1 2267/4885ANPEP 935/4885RNPEP 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.